| May 1 |
Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of
Generic Product by Novopharm Prohibited until 2014 |
| May 1 |
New Hampshire Law Banning Commercial Use of Prescription
Information Declared Unconstitutional |
| May 1 |
Ista Pharma Ltd Withdraws Its Marketing Authorisation Application
for Vitragan |
| May 1 |
Lilly to Publish Information on Grants and Contributions |
| May 1 |
Astellas and Theravance Announce Submission of Telavancin MAA for
the Treatment of Complicated Skin and Soft Tissue Infections in
Europe |
| May 1 |
IMPAX Reports SEC Actions |
| May 1 |
MedImmune Reports Financial Results for 2007 First Quarter |
| May 1 |
Response Submitted to FDA Approvable Letter for Hypertension
Compound Nebivolol |
| May 1 |
FDA Warns Consumers About Counterfeit Drugs From Multiple Internet
Sellers |
| May 1 |
Baxter Executives Provide Update on Progress at Annual Shareholder
Meeting |
| May 1 |
Inex Pharmaceuticals Announces Completion of Spin-out of Tekmira
Pharmaceuticals Corporation |
| May 1 |
Eurand Files IPO Registration Statement with SEC |
| May 1 |
First of Its Kind Data Show: Immediate Treatment of Early MS
Patients with Betaseron Significantly Delayed Permanent Disability |
| May 1 |
Physicians Practice Acquired by United Business Media |
| May 2 |
Biogen Idec Reports First Quarter 2007 Results |
| May 2 |
Teva Reports First Quarter 2007 Results |
| May 2 |
CollaGenex Pharmaceuticals Provides Update on 40 mg Cohort of Phase
II Dose-Finding Study of Incyclinide for the Treatment of Acne |
| May 2 |
FDA Approves Oscient Pharmaceuticals' Factive Tablets for Five-Day
Treatment of Community-Acquired Pneumonia |
| May 2 |
FDA Advisory Committee Finds Substantial Evidence to Support Advair
500/50 in Reducing COPD Exacerbations |
| May 2 |
FDA Approves Fragmin as First Low-Molecular-Weight Heparin for
Extended Treatment to Reduce the Recurrence of Blood Clots in
Patients with Cancer |
| May 2 |
Novo Nordisk: Financial statement for the period 1 January 2007 to
31 March 2007 (2 May 2007) |
| May 2 |
Pfizer Launches Online Initiative Disclosing Its U.S.
Post-Marketing Commitments |
| May 2 |
Bristol-Myers Squibb Breaks Ground on New Biologics Manufacturing
Facility in Massachusetts |
| May 2 |
FDA Proposes New Warnings About Suicidal Thinking, Behavior in
Young Adults Who Take Antidepressant Medications |
| May 2 |
Allergan Reports First Quarter Operating Results |
| May 2 |
Sunesis Pharmaceuticals Announces Preclinical Milestone Payment in
BACE Collaboration with Merck |
| May 2 |
New Critical Path Report Highlights Research Needed to Foster
Generic Drug Development |
| May 3 |
Vyvanse (lisdexamfetamine dimesylate) Receives Final DEA Schedule
Classification, Clearing Way for Launch of First Prodrug Stimulant
for Treatment of ADHD |
| May 3 |
sanofi-aventis: Full-year Guidance Raised on Good 2007
First-Quarter Results |
| May 3 |
Medarex to Receive Milestone Payment from Amgen |
| May 3 |
Statement by Merck & Co., Inc., Regarding the Fracture
Intervention Trial with Fosamax (alendronate sodium) and Incidence
of Atrial Fibrillation |
| May 3 |
Morgan Keegan To Acquire Shattuck Hammond Partners |
| May 3 |
GPC Biotech Consolidates Drug Discovery Activities |
| May 3 |
Medicis Announces FDA Approval of Perlane |
| May 3 |
Mylan Announces Tentative FDA Approval for Letrozole Tablets, USP |
| May 3 |
GPC Biotech AG (DE) - GPC Biotech Consolidates Drug Discovery
Activities |
| May 3 |
Senate Committee on Finance Responds to ACCME |
| May 3 |
Takeda Pharmaceutical First Sponsor In New Healthcare Broadband
Platform |
| May 3 |
Former Serono Employee Not Guilty in Health Care Fraud Case |
| May 4 |
Dyax Announces the Resignation of Thomas Beck, M.D., President and
Chief Operating Officer |
| May 4 |
Rx for Africa, Inc. Announces Merger with Rx Africa (Ethiopia) PLC
and Diamond Entertainment Corporation |
| May 4 |
Treatment with Copaxone Plus Minocycline Showed Substantial
Reduction of Disease Activity in Patients with Active
Relapsing-Remitting Multiple Sclerosis |
| May 4 |
Schering-Plough Receives Request for Additional Information From
Federal Trade Commission in Connection With Planned Organon
Biosciences N.V. Transaction |
| May 4 |
Pharmaceutical Whistleblowers Tell Their Tales Through Blogs,
Congress Responds |
| May 4 |
Merck & Co., Inc. Statement on Brazilian Government's Decision
To Issue Compulsory License for Stocrin |
| May 4 |
MarketResearch.com Acquires Thomson Business Intelligence (TBI)
Market Research (Profound) Service |
| May 4 |
Devax, Inc. Files Registration Statement for Proposed Initial
Public Offering |
| May 7 |
FDA Advises Manufacturers to Test Glycerin for Possible
Contamination |
| May 7 |
Takara Bio Grants Transgenomic License for LA-PCR Technology |
| May 7 |
Adverse Event of FG-2216 for the Treatment of Anemia |
| May 7 |
Overseas Co-Promotion of Actemra, a Treatment for Rheumatoid
Arthritis |
| May 7 |
Official Completion of New Patient Enrollment of Post Marketing
Surveillance on Enbrel Shows Encouraging Results for Patients and
Physicians |
| May 7 |
CollaGenex Pharmaceuticals Discontinues 40 mg Cohort of Phase II
Dose-Finding Study of Incyclinide for the Treatment of Acne |
| May 7 |
Affitech Signs Antibody Research and Licensing Agreement with Roche |
| May 7 |
Peptech and Evogenix Merge to Form Antibody Powerhouse |
| May 7 |
Bayer HealthCare and Intendis Announce Strategic Alliance to
Co-Promote Yaz (Drospirenone/Ethinyl Estradiol) for Treatment of
Moderate Acne |
| May 7 |
Pfizer Partners with Canadian Policymakers to Continue Shaping an
Environment Conducive to Research and Innovation |
| May 7 |
AstraZeneca to Begin Construction for $100M Research Investment at
R&D Boston; Expansion Solidifies Company's Commitment to
Massachusetts as a Scientific and Biotech Hub |
| May 7 |
Viragen Shifts Development Focus for Anti-Cancer Products |
| May 7 |
USA for Innovation Launches ThaiLies.com |
| May 8 |
inVentiv Health Announces Executive Management Changes |
| May 8 |
AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights from
Solvay for Cetrorelix in Endometriosis Indication |
| May 8 |
AARP Welcomes Senate Passage of Rx Importation, but Promises to
Fight Unnecessary Importation Roadblocks |
| May 8 |
AARP Welcomes Senate Passage of Rx Importation, but Promises to
Fight Unnecessary Importation Roadblocks |
| May 8 |
AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights from
Solvay for Cetrorelix in Endometriosis Indication |
| May 8 |
Solvay Group First Quarter 2007 Results |
| May 8 |
CEOS Up $1.26 Billion, Shareholders Down $330 Billion |
| May 8 |
Bayer Publishes Interim Report for the First Quarter of 2007 |
| May 8 |
Bradley Pharmaceuticals Announces Resignation of Dr. Leonard S.
Jacob as Non- Executive Chair, Appointment of Seth W. Hamot as
Interim Non-Executive Chair |
| May 8 |
Medicis Pharmaceutical to Pay U.S. $9.8 Million to Resolve False
Claims Allegations |
| May 8 |
Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension,
250 mg/5 mL, Launches Entire Product Family |
| May 8 |
Singapore Attracts Four Major Biologics Manufacturing Investments
Totaling Close to US$1 Billion in Less Than Two Years |
| May 9 |
Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration
With Isis Pharmaceuticals |
| May 9 |
Study by Cardiologists at Northwestern Memorial Reveals a High
Percentage of Heart Patients Receive Off-Label and Untested
Drug-Coated Stents |
| May 9 |
Lilly Announces New Employee Policy |
| May 9 |
Hospira Reports First-Quarter 2007 Results |
| May 9 |
Somaxon Pharmaceuticals Provides Update on Silenor Development
Program |
| May 9 |
FDA Re-Inspection Results in Positive Re-Classification of Guayama
Facility |
| May 9 |
Abbott Highlights Strong Performance in Corporate Social
Responsibility in 2006 Global Citizenship Report |
| May 9 |
Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type
Disasters; House Urged to Act on Strong Drug Safety Bill |
| May 10 |
Biosite Receives Revised Offer From Inverness Medical Regarding
Possible Cash Tender Offer |
| May 10 |
King Pharmaceuticals Reports First-Quarter 2007 Financial Results |
| May 10 |
FDA Sends Letter to GlaxoSmithKline Regarding Flonase Aid |
| May 10 |
FDA Sends Letter to Schering Over Nasonex Detail Aid |
| May 10 |
Statement of Purdue Pharma Regarding Resolution of the Federal
Investigation in the Western District of Virginia |
| May 10 |
Gene Logic and Abbott Enter Collaboration to Discover New
Development Paths for Multiple Clinical Drug Candidates |
| May 10 |
Dendreon Reports First Quarter 2007 Financial Results |
| May 11 |
Asterand plc, Bristol-Myers Squibb Sign Further Agreements for
Access to Asterand Products and Services |
| May 11 |
Bristol-Myers Squibb Announces Agreement in Principle to Resolve
Federal Antitrust Investigation |
| May 11 |
Pharmaceutical Bloggers Busy This Week with Discussions of FDA
Revitalization Act and Off-label Marketing |
| May 14 |
Teva Comments About the Acquisition of Merck KGaA Generic Business |
| May 14 |
Mylan Laboratories to Acquire Generics Business of Merck KGaA |
| May 14 |
Eisai Obtains Favorable Ruling in Aciphex Patent Infringement
Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories |
| May 14 |
Cardinal Health to Acquire Medical Technology Leader VIASYS
Healthcare for $1.5 Billion |
| May 14 |
Southern District Court of New York Rules Patent for Aciphex
Enforceable |
| May 14 |
Biovail Acknowledges Receipt of Wells Notice |
| May 14 |
Oral Pleadings in Implanon Appeal |
| May 14 |
Recall of Two Valproic Acid Drugs, Depakene 500 mg and
Ratio-Valproic 500 mg |
| May 14 |
Critical Therapeutics' Sales Force Gains Access to a Second Product
as FDA Approves Co-Promotion Partner's New Treatment for COPD |
| May 14 |
Bayhill Therapeutics Appoints Fred Kurland as Chief Financial
Officer |
| May 14 |
P&G Announces Business Unit Realignment |
| May 15 |
King Pharmaceuticals Receives DHS Safety Act Designation and
Certification for AtroPen |
| May 15 |
Eisai Signs Exclusive Agreement to Commercialize NeuroBloc for
Europe |
| May 15 |
President and CEO of Advanced Viral Research Corp. Signs on for an
Additional Two Years |
| May 15 |
Sanofi-Aventis Calls for an Effective Policy Against Drug
Counterfeiting |
| May 15 |
GSK Returns Development Rights for MED2002 |
| May 15 |
Results Mixed on Postmarketing Studies of New Drugs, According to
the Tufts Center for the Study of Drug Development |
| May 15 |
Commonwealth Biotechnologies, Inc. Announces Definitive Agreement
to Acquire Tripos Discovery Research Ltd |
| May 15 |
Proteros Biostructures and Boehringer Ingelheim Pharmaceuticals
Enter into Protein Crystallography Agreement |
| May 16 |
Biovail Acknowledges Wells Notices Received by Company Executives |
| May 16 |
Wyeth Wins Philadelphia Hormone Therapy Trial |
| May 16 |
Biovail Chairman Eugene Melnyk Announces Retirement |
| May 16 |
Increases in Medication Use Among 10 to 19 Year-old Girls for
Several Chronic and Behavioral Conditions Far Outpaces Boys of the
Same Age |
| May 16 |
Bausch & Lomb Enters into Merger Agreement with Warburg Pincus |
| May 16 |
Bausch & Lomb Enters into Merger Agreement with Warburg Pincus |
| May 16 |
pSivida Redeems Convertible Note Debt |
| May 16 |
Pharmacia and Upjohn Will Appeal Verdict in Simon Case, 'Ruling is
Not Supported by the Evidence' |
| May 16 |
Corporate Philosophy and Vision, Brand Mark, Business Management
Goals and Other Policies of Mitsubishi Tanabe Pharma Corporation |
| May 17 |
AAIPharma Strengthens South American Operations through Acquisition
of Instituto de Pesquisa Clinica de Sao Paulo, Ltd. |
| May 17 |
Cardinal Health Names Scott Storrer Group President, Healthcare
Supply Chain Services-Pharmaceutical |
| May 17 |
New Report: Unmanaged, Diabetes Drug Costs Could Surge Nearly 70
Percent Within Three Years |
| May 17 |
ImmunoGen, Inc. Announces Resignation of Howard Pien from its Board
of Directors |
| May 17 |
Dramatic Cost Discrepancies Revealed in AG's Investigation of Drug
Prices Statewide |
| May 17 |
10th Annual National Survey On Consumer Reaction To DTC
Pharmaceutical Advertising Reveals #1 Action Taken After Seeing DTC
Ad: |
| May 18 |
New Report: Unmanaged, Diabetes Drug Costs Could Surge Nearly 70
Percent within Three Years |
| May 18 |
Britain's NAO: Prescribing Costs in Primary Care |
| May 18 |
Pharmaceutical Industry Remains Anxious About Challenges Presented
by Blogs and Michael Moore’s Latest Documentary |
| May 21 |
KineMed Evaluates the Mechanism of Action for Colesevelam in
Patients With Type 2 Diabetes |
| May 21 |
Talabostat Clinical Program Put on Clinical Hold by FDA |
| May 21 |
AMRI Acquires Manufacturing Facilities in India |
| May 21 |
Tibolone Study in Breast Cancer Patients to Close Ahead of Schedule |
| May 21 |
Roche Receives Approvable Letter for Mircera in the United States |
| May 21 |
Pfizer Says Research and Development Head John LaMattina Will
Retire This Year |
| May 21 |
Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab
(AAB-001) in Alzheimer's Disease |
| May 21 |
Novartis Defends Its Intellectual Property Rights as US Court
Issues Order Prohibiting Teva from Selling a Generic Version of
Lotrel |
| May 21 |
Questcor Announces Departure of CEO James Fares |
| May 21 |
Champions Biotechnology, Inc. Acquires Biomerk, Inc. |
| May 21 |
Thermo Fisher Scientific and Quintiles Create Joint Venture to
Provide Integrated Response Technology Services |
| May 21 |
GlaxoSmithKline Responds to NEJM Article on Avandia |
| May 21 |
FDA Issues Safety Alert on Avandia |
| May 22 |
GlaxoSmithKline Strongly Defends its Record on Avandia |
| May 22 |
Medtronic Announces Start of 8,800-Patient Clinical Trial
Evaluating Drug-Eluting Stent Safety |
| May 22 |
Statement from the American College of Cardiology, American
Diabetes Association and American Heart Association Related to NEJM
article, 'Effect of Rosiglitazone on the Risk of Myocardial
Infarction and Death from Cardiovascular Causes' |
| May 22 |
Taro Merger with Sun Proceeds after Favorable Court Ruling in
Israel |
| May 22 |
Chairman Baucus and Ranking Member Grassley Comment on New England
Journal of Medicine Report on Avandia |
| May 22 |
FDA - MedWatch - Exjade (deferasorix) Tablets For Oral Suspension:
Changes Made to The Warnings and Adverse Reactions Sections of
Prescribing Information |
| May 22 |
FDA Sends Letter to KV Pharmaceutical About Clindesse E-Mail/Alert |
| May 23 |
Vion Announces Suspension of Phase III Trial in Relapsed AML |
| May 23 |
DRAXIS Manufacturing Facilities Pass Extensive FDA Inspection |
| May 23 |
Organon and Philips Team up to Study Drug Effects at the Molecular
Level |
| May 23 |
Third Point Appeals to Unconflicted Directors of PDL BioPharma;
Seeks Resignation of Board Chairman as Well as CEO |
| May 23 |
PhRMA Meets with Thai Health Minister; Highlights Consequences of
Compulsory Licenses |
| May 23 |
Medidata Solutions Achieves Largest Revenue Quarter in Company
History |
| May 23 |
FDA Requests Boxed Warning for Contrast Agents Used to Improve MRI
Images |
| May 23 |
PhRMA Web Site Features New Drug/Patient Safety Info |
| May 23 |
Knott Partners Expresses Concern Regarding Proposed BioVeris-Roche
Transaction |
| May 24 |
Judicial Watch Uncovers Three Deaths Relating to HPV Vaccine |
| May 24 |
Judicial Watch Uncovers Three Deaths Relating to HPV Vaccine |
| May 24 |
CV Therapeutics Significantly Reduces Operating Expenses |
| May 24 |
Mylan Reports Fourth Quarter & Fiscal 2007 Adjusted Diluted EPS
of $0.47 & $1.65 Excluding any Contribution from Amlodipine |
| May 24 |
EMEA Statement on Recent Publication on Cardiac Safety of
Rosiglitazone (Avandia, Avandamet, Avaglim) |
| May 24 |
STARLIMS Technologies Ltd. Announces Public Offering of Its
Ordinary Shares in the United States at a Price Per Share of $13.50
with Net Proceeds to the Company of Approximately $25.5 Million |
| May 24 |
Neose Receives Milestone Payment From Novo Nordisk on Factor IX
Program |
| May 24 |
Annual Stockholders’ Meeting of Bayer Schering Pharma AG,
Berlin, Germany: Integration of Bayer Schering Pharma Progressing
Rapidly |
| May 24 |
GlaxoSmithKline Launches Chinese R&D Centre with Appointment of
Head in Shanghai |
| May 24 |
Helicos Biosciences Prices Initial Public Offering |
| May 24 |
FDA Sends Warning Letter to Enzon Over Abelcet Flash Card |
| May 24 |
Hispanics and African Americans Among Those at Risk Due to High
Cost of Prescription Drugs |
| May 25 |
VaxGen Completes Development Activity in Support of Anthrax Vaccine
Partnering Effort and Reduces Associated Staff |
| May 25 |
Recall of counterfeit Zyprexa batches |
| May 25 |
Pharma Bloggers Express Differing Opinions on Avandia Revelation
and Departure of Pfizer CFO Alan Levin |
| May 25 |
FDA Takes Action Against Unapproved Timed-Release Guaifenesin
Products, Including Prescription Versions of Mucinex DM and Mucinex
D |
| May 29 |
Purdue Pharma L.P. Announces End of OxyContin Patent Lawsuit With
IMPAX Laboratories |
| May 29 |
Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in
Norway |
| May 29 |
Bradley Pharmaceuticals Announces Receipt of 'Going Private'
Proposal at $21.50 Per Share Establishment of Special Committee |
| May 29 |
Shanghai Century Acquisition Corporation Announces Proposed
Business Combination With Kelun Pharmaceutical, China's Largest
Producer of IV Solution Products |
| May 29 |
Patient Compliance: Is There a Solution? Consumers Weigh in on the
Questions and Answers of Complying with Drug Regimens |
| May 30 |
Us Court Continues to Prevent Teva from Shipping Any Additional
Generic Copies of the High Blood Pressure Medicine Lotrel |
| May 30 |
Biowa and Takeda Announce Licensing of Biowa's Potelligent
Technology for Use in Antibody Research and Development |
| May 30 |
Norwalk, Ohio Mother Sues Bayer Healthcare Pharmaceuticals for the
Death of Her 24-Year-Old Son |
| May 30 |
At $42 Billion by 2011, Immunological and BioTherapy Cancer
Treatments Near 50% of Market! |
| May 30 |
Gabelli Equity Trust Inc. Shareholders Approve Spin-off of the
Gabelli Healthcare & Wellness(Rx) Trust |
| May 30 |
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety
Profile |
| May 30 |
Investor Alert From Cauley Bowman Carney & Williams, PLLC:
Update on Proposed Acquisition of Bradley Pharmaceuticals, Inc. -
BDY |
| May 31 |
Bristol-Myers Squibb Pleads Guilty to Lying to the Federal
Government About Deal Involving Blood-Thinning Drug |
| May 31 |
FDA Sends Warning Letter to Allergan Regarding Acular Advertisement |
| May 31 |
Medarex Announces Collaborative Research Agreement with Mitsubishi
Pharma |
| May 31 |
Point Therapeutics Reduces Costs by Cutting Work Force |
| May 31 |
Philadelphia Hormone Therapy Verdict Overturned in Favor of Wyeth |
| May 31 |
AtheroGenics Announces Business Plan to Focus on Advancing AGI-1067
in Diabetes |
| May 31 |
Point Therapeutics Reduces Costs by Cutting Work Force |
| May 31 |
Swissmedic Orders the Withdrawal of Zelmac for Irritable Bowel
Syndrome |
| May 31 |
inVentiv Health Acquires Addison Whitney, Full Service Global Brand
Identity and Consulting Firm |
| May 31 |
KFDunn Merges with Aloysius Butler & Clark to Form New
Division: KFDunn Life Sciences Marketing Communications |
| May 31 |
Advanced Cell Technology Enters Into Letter of Intent to Acquire
Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing
Myoblasts for the Treatment of Heart Failure |
| May 31 |
Third Point Asks Unconflicted Directors of PDL BioPharma to
Conclude Investigation Into CEO McDade's Suspected Ethical and
Business Breaches as Expeditiously as Possible |
| May 31 |
FDA Finalizes Guidances For Pandemic and Seasonal Influenza
Vaccines |
| May 31 |
HealthShares Announces Changes to the HealthShares Infectious
Disease, Respiratory/Pulmonary, Cancer, and Composite Indexes |
